News

Barchart on MSN17h
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
BioSpace1d
KalVista Wins OK for First On-Demand Hereditary Angioedema Pill
Ekterly’s road to approval was not a smooth one. Last month, the FDA informed KalVista it would not meet its PDUFA date due ...
Kalkine Media1d
FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista
KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...
BMJ Case Reports2d
Hereditary angioedema in a paediatric patient presenting with abdominal pain and duodenal dilation
Hereditary angioedema (HAE) is a genetic disorder that causes sudden episodes of swelling, often accompanied by abdominal pain. Affecting roughly 1 in 50 000 people, HAE typically appears in childhood ...
Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)
Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...
Newseria BIZNES6d
Hereditary Angioedema (HAE): Competitive Intelligence Insight into Next-Gen Treatment Strategies | DataM Intelligence
Hereditary Angioedema (HAE) is a rare genetic disorder marked by sudden, severe swelling episodes in the skin, gut, or airway ...
Leading Factor Driving The Angioedema Treatment Market In 2025: Rise In Rare Disease Diagnoses Fueling The Growth
Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...